Georgiamune Doses First Participant in Phase 1 Trial of GIM-407 for Autoimmune Diseases
• Georgiamune has dosed the first participant in a Phase 1 trial of GIM-407, an oral, selective T-regulatory cell activator, for autoimmune diseases.
• GIM-407 represents Georgiamune's first autoimmune disease program and is based on novel biology, with potential application to various autoimmune conditions.
• The Phase 1 trial will assess the safety, tolerability, and pharmacokinetics of GIM-407 in healthy volunteers to inform future trials in specific autoimmune diseases.
• Georgiamune has initiated three first-in-class assets in clinical trials in the past 12 months, highlighting its commitment to developing innovative therapies.
© Copyright 2025. All Rights Reserved by MedPath